Opiant Pharmaceuticals, Inc.
OPNT · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 7,375.2% | 6.1% | -83.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 77.8% | 80.6% | 77.6% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -5.4% | -485.6% | -536.9% | 14.3% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -5.7% | -504.6% | -574% | 5.8% |
| EPS Diluted | -1.93 | -2.31 | -2.51 | 0.13 |
| % Growth | 16.5% | 8% | -2,030.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |